Epinephrine is crucial for treating anaphylaxis but its cardiovascular side effects may make clinicians hesitant to use it; this study aimed to evaluate the frequency of such cardiotoxic effects.
A retrospective study in a Tennessee ED looked at 338 adult patients treated with intramuscular epinephrine for anaphylaxis from 2017 to 2021, primarily assessing cardiotoxicity defined by specific heart-related outcomes.
The results showed that about 4.7% of patients experienced cardiotoxicity, with older patients and those with more health issues being at a higher risk, especially if they received multiple doses of epinephrine.